A novel upper gastrointestinal bleeding risk stratification score (AIMS65) has 
recently been developed and validated. It has advantages over existing risk 
scores including being easy to remember and lack of subjectivity in calculation. 
We comment on a recent study that has cast doubt on the applicability of AIMS65 
in the peptic ulcer disease population. Although promising, further studies are 
required to evaluate the validity of AIMS65 in various populations.